190 related articles for article (PubMed ID: 11878047)
1. Monoclonal antibodies conjugated with radioisotopes for the treatment of Non-Hodgkin's lymphoma.
Bush S
Semin Oncol Nurs; 2002 Feb; 18(1 Suppl 1):16-21. PubMed ID: 11878047
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
Hendrix CS; de Leon C; Dillman RO
Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy for non-Hodgkin's lymphoma.
Liebenguth P; Vogt Temple S
Semin Oncol Nurs; 2006 Nov; 22(4):257-66. PubMed ID: 17095402
[TBL] [Abstract][Full Text] [Related]
4. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
Bischof Delaloye A
Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
[TBL] [Abstract][Full Text] [Related]
5. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
[TBL] [Abstract][Full Text] [Related]
6. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Riley MB; Gordon LI
Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):8-13. PubMed ID: 15160856
[TBL] [Abstract][Full Text] [Related]
8. Radiation safety with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy.
Hendrix C
Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):14-9. PubMed ID: 15160857
[TBL] [Abstract][Full Text] [Related]
9. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
10. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
[TBL] [Abstract][Full Text] [Related]
11. Logistics of therapy with the ibritumomab tiuxetan regimen.
Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S35-8. PubMed ID: 16979437
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
13. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394
[TBL] [Abstract][Full Text] [Related]
14. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
15. Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.
Schaefer-Cutillo J; Friedberg JW
Semin Hematol; 2008 Apr; 45(2):110-7. PubMed ID: 18381106
[TBL] [Abstract][Full Text] [Related]
16. [Indications for radioimmunotherapy for patients with non-Hodgkin's lymphoma].
Frølund UC; Hansen PB
Ugeskr Laeger; 2011 May; 173(20):1417-21. PubMed ID: 21586245
[TBL] [Abstract][Full Text] [Related]
17. The rationale for and background of radioimmunotherapy: an emerging therapy for B-cell non-Hodgkin's lymphoma.
Riley MB; Byar K
Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):1-7. PubMed ID: 15160855
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
Pauwels EK; Erba P
Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631
[TBL] [Abstract][Full Text] [Related]
19. Radiation safety guidelines for radioimmunotherapy with yttrium 90 ibritumomab tiuxetan.
Hendrix C
Clin J Oncol Nurs; 2004 Feb; 8(1):31-4. PubMed ID: 14983760
[TBL] [Abstract][Full Text] [Related]
20. Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma.
Multani P
Int J Hematol; 2002 Dec; 76(5):401-10. PubMed ID: 12512834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
